• Every year 7 million people die from cancer
• 16 million new cancer cases and 10 million deaths are expected by 2020
• Yet cancer can be one of the most preventable and curable of the life-threatening diseases

This atlas is a unique resource for professionals and individuals in the global battle to reduce cancer.

It illustrates compelling data from around the world in full colour maps and graphics to provide a clear picture and better understanding of cancer locally, nationally and globally. It shows the causes, stages of development, and rates of different types of cancers by sex, income group and region. It also examines the economics of the disease, both in terms of healthcare and commercial interests, and the steps being taken to curb the epidemic, from research and screening to cancer management programmes and health education.

Topics include:
- Mechanism of tumour development
- Risk factors: tobacco, reproductive and hormonal factors, infection, diet and nutrition, and ultraviolet radiation
- Cancer in children
- Cancer survivors
- Cancer registries
- Research
- Primary prevention
- Early detection
- Management and treatment
- Cancer organizations
- Health education
- Policies and legislation
- The future of the epidemic

Dr Judith Mackay
Dr Ahmedin Jemal
Dr Nancy C Lee
Dr D Maxwell Parkin
THE CANCER ATLAS
Part Six: THE FUTURE & THE PAST

27 The future 82
The cancer epidemic, risk factors, and action, projected to 2030. New cancer cases by WHO region.

The history of cancer 84
From the early description of cancer thousands of years ago to the present day, landmarks in first descriptions, diagnosis and treatment, establishment of organizations, identification of risk factors, conferences and action taken.

Part Seven: WORLD TABLES

Table A: Risk factors for cancer 92
Prevalence of youth and adult smoking, and of overweight.

Table B: Statistics on cancer 100

Sources 108
Useful contacts 123
Index 127
A message from
John R Seffrin, PhD
Chief Executive Officer
American Cancer Society

Cancer is potentially one of the most preventable and curable chronic life-threatening diseases. Nevertheless, in 2002 there were an estimated 11 million new cancer cases and nearly 7 million cancer deaths worldwide. By 2020, more than 16 million new cancer cases and 10 million deaths are expected. Seventy percent of these deaths will likely occur in developing countries that are unprepared to address their growing cancer burdens.

We know cancer can be controlled. Declining mortality rates for many cancers in developed nations prove it. But without aggressive intervention, similar results may not be seen elsewhere. Real progress requires a concerted effort at all levels of society. That’s why the American Cancer Society and the International Union Against Cancer offer programmes designed to help the global cancer community – especially emerging cancer societies – achieve long-term success in cancer control. Along with our partners at the Centers for Disease Control and Prevention and International Agency for Cancer Research, we are working to lay a foundation for global cancer control and prevention.

Because these organizations share ambitious goals, I am proud to welcome the timely publication of The Cancer Atlas, another important step in our collective effort. Here are compelling, evidence-based data to help cancer control experts around the world combat the disease locally, nationally, and globally. Information is a powerful tool in the hands of passionate, dedicated individuals, and this book is an important new resource to arm and inform cancer control professionals worldwide.

In addition to the leading-edge information we need to inform our cancer control strategies, The Cancer Atlas also provides an intangible, powerful weapon – hope. The significant and exciting updates chronicled within these pages prove that our broad network of determined cancer control professionals are making a difference for the world. Together, we can empower the developing world to alleviate its cancer burden. With The Cancer Atlas in our arsenal, we will continue to move toward victory over cancer.

JOHN R SEFFRIN
Atlanta, USA

A message from
Julie Louise Gerberding, MD, MPH
Director
Centers for Disease Control and Prevention

The Centers for Disease Control and Prevention is pleased to have played a role in producing the first-ever Cancer Atlas, the third in a series of atlases describing important issues related to chronic diseases worldwide.

The cancer community has made extraordinary progress in many parts of the world. In Europe, death rates for several common cancers are decreasing steadily, and in the USA, death rates from all cancers combined have dropped 1.1 percent per year since 1993. These successes are due in part to public health efforts targeting prevention and early detection of cancer, as well as advances in cancer treatment.

Nonetheless, approximately 11 million people worldwide are diagnosed with cancer annually, and almost 7 million people die of the disease each year. Additionally, more than 25 million people are surviving for years after a cancer diagnosis. A troubling fact is that cancer incidence, survival rates, and quality of life for survivors vary greatly from country to country, depending on differences in exposure to risk factors, availability of public health resources for cancer control efforts, and access to the latest advances in screening and treatment. For example, cervical cancer is the leading cancer in women in developing countries, where organized screening programmes do not exist. In developed countries, where cervical cancer screening is widespread, cervical cancer accounts for only four percent of cancers in women.

To address these disparities, public health agencies and organizations worldwide are assessing local resources, enhancing healthcare infrastructure, and implementing proven cancer-prevention strategies. These strategies must include efforts to prevent the initiation of smoking among adolescents, combat the rise in smoking among women in developing countries, increase the use of proven screening and early-detection methods, and close the large gap in health resources between rich and poor nations.

As the public health community works toward relieving the worldwide burden of cancer, it is important that we consider the entire cancer continuum – from prevention through screening, early detection, diagnosis, treatment, survivorship, palliation, and end-of-life care. To ensure success, we must join forces with researchers, healthcare providers, the private sector, and governments.

I encourage you to use this atlas to improve and inform your efforts to prevent and control cancer.

JULIE LOUISE GERBERDING
Atlanta, USA

FOREWORDS
A message from

Peter Boyle
Director of the International Agency for Research on Cancer

F orty years ago, when the International Agency for Research on Cancer (IARC) was established, cancer was a disease largely confined to the industrialized, high-resource countries. Today, in marked contrast, the majority of the global cancer burden is in low- and medium-resource countries. This atlas illustrates the global scope of the cancer epidemic – highlighting the variations, similarities and sex differences in cancer incidence and deaths. While there are several clearly identified risk factors and we are steadily learning about additional risk factors, there remains a significant proportion of the global cancer burden that we are unable to explain, or advocate steps to avoid, within our current knowledge. The atlas also highlights the importance of cancer surveillance systems, including registries, and of cancer research. These are essential to our understanding of the epidemic, of planning resources, and of taking preventive action.

The IARC is part of the World Health Organization. The Agency’s work has four main objectives: monitoring global cancer occurrence, identifying the causes of cancer, elucidating the mechanisms of carcinogenesis, and developing scientific strategies for cancer control. The role of IARC among cancer research institutes is characterized by its focus on research of direct relevance to cancer prevention in international populations, by its emphasis on studies that combine epidemiological and laboratory approaches, and by the special forum and support it provides for international collaborations.

The main emphasis of IARC’s research programme is on epidemiology and environmental carcinogenesis and IARC also makes a significant contribution in the area of research training. This emphasis reflects the generally accepted notion that 80 percent of all cancers are, directly or indirectly, linked to environmental factors, and thus are potentially preventable; second, the recent recognition of the fact that epidemiology may play an important part in cancer prevention and in the evaluation of prevention measures; lastly, the fact that geographical variations in cancer incidence almost certainly reflect differences in the environment and are therefore particularly well suited for international research efforts.

Epidemiological research is thus orientated towards two areas: on the one hand, descriptive studies show the trends of cancer incidence and mortality in different populations and geographical areas and, on the other hand, analytical studies focus on the relationships between incidence and mortality and specific risk factors (tobacco use, alcohol consumption, chronic infections, diet, some professional exposures, etc). IARC is, therefore, different from all other research institutes, in that it brings an international dimension to studies on human cancer and the relationships of people and their environment.

I commend the authors of this atlas for bringing a strong sense of the global nature of the cancer burden throughout this book. As Director of the IARC, I am very pleased to see that much of the data used in this atlas is from the IARC database, thus giving the collected statistics a wider audience.

Peter Boyle
Lyon, France

With full-colour maps and graphics, this atlas illustrates the world’s cancer burden and describes efforts to address that burden. It also includes historical highlights, predictions for the future and useful contact information. Readers will learn about the various risk factors for cancer; the costs of cancer; the remarkable differences and similarities in the patterns of cancer around the world; and efforts to prevent, detect and treat cancer. The atlas is for anyone concerned about cancer, including cancer survivors, their families and friends. It is also for those concerned with health policy, public health, health economics, gender issues, resource allocation and human development.

Highlighting the fact that the burden of cancer is increasing in developing countries, which have fewer resources to address the problem, the atlas asserts the importance of a multifaceted approach to reducing the burden of cancer. Such an approach requires the participation of governmental agencies in many nations, the business sector, non-profit organizations, the World Health Organization and the general public. In short, it requires the input of all of civil society.

The anti-cancer movement has developed many successful strategies contributing to the control of cancer around the world, and this atlas highlights a few of those successes, including the establishment of cancer registries; research efforts in developing and developed countries; breakthroughs in prevention, early detection and treatment; and improvements in the lives of those affected by cancer.

Judith Mackay
Asian Consultancy on Tobacco Control
Hong Kong SAR, China

Ahmedin Jemal
American Cancer Society
Atlanta, USA

Nancy C Lee
Centers for Disease Control and Prevention
Atlanta, USA

D Maxwell Parkin
University of Oxford
UK
Particular thanks go to the American Cancer Society and to the Centers for Disease Control and Prevention, USA, for their generous financial support of this atlas, and to the International Agency for Research on Cancer for their helpful comments. The International Union Against Cancer (UICC) supplied much helpful information, for which we are grateful. We would also like to thank the World Health Organization, in particular the International Agency for Research on Cancer, for supplying datasets, and for useful suggestions and advice.

Many people have helped in the preparation of this atlas. We would particularly like to thank our principal researchers: Brook Raflo, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, USA; Nicole Schrag, Department of Epidemiology and Surveillance Research, American Cancer Society, USA.

We would like to acknowledge the following people at the American Cancer Society and the Centers for Disease Control and Prevention: Kevin Brady, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, USA; Ralph Coates, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, USA; Michael Thun, Epidemiology and Surveillance Research, American Cancer Society, USA.

For their advice on particular maps and subjects, we would like to thank the following:

1 Mechanism of tumour development

2 Risk factors
Robert C Burton, National Cancer Control Initiative, Australia; Cynthia Jorgensen, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, USA; Mona Saraiya, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, USA.

3 Risks for boys and 4 Risks for girls
Cheryll J Cardinez, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, USA; Yumiko Mochizuki-Kobayashi, Tobacco Free Initiative, World Health Organization, Vick Warren, Office on Smoking and Health, Centers for Disease Control and Prevention, USA.

5 Tobacco
Jaclynn Lippe, Department of Chronic Diseases and Health Promotion, World Health Organization, Kate Strong, Surveillance and Information for Policy, World Health Organization.

8 Ultraviolet radiation

13 Major cancers

14 Cancer in children
Dr Eva Steliarova-Foucher, International Agency for Research on Cancer.

15 Cancer survivors
Darnelle Bernier, International Relay For Life, American Cancer Society, USA; Jose Julio Divino, Campaign and Communications Cluster, International Union Against Cancer; Lori A Pollack, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, USA.

16 Economic costs
Evan H Blecher, School of Economics, University of Cape Town, South Africa; Corne F van Walbeek, School of Economics, University of Cape Town, South Africa.

18 Cancer registries
The International Association of Cancer Registries.

20 Primary prevention
Andri Arisotelous, Ministry of Health, Cyprus; Inmaculada Castro Rodriguez, Dirección General de Salud Pública, Consejería de Sanidad y Consumo, Murcia, Spain; Ian G Catchpole, Ipsos Health, UK; Jacques Fracheboud, Dept of Public Health, Netherlands; Michael Kightley, Chairman, Public Affairs Committee, United European Gastroenterology Federation, UK; Paola Mantellini, Istituto Scientifico della Regione Toscana, Italy; Lola Salas Trejo, Jefa de Unidad de Prevención de Cáncer, Oficina Plan del Cáncer, Dirección General de Salud Pública, Consellería de Sanitat, Valencia, Spain; Maja Premsekloj, Professor, Institute of Oncology, Slovenia; Raquel Zubizarreta Alberdi, Jefa de Servicio, Dirección Xeral de Saúde Pública, Consellería de Sanidade, Galicia, Spain.

24 Cancer organizations

25 Health education
Marjo Pyykönen, International Quit&Win, Finland; Geoff Thaxter and Marianne C Naafs-Wilstra, International Confederation of Childhood Cancer Parent Organizations.

26 Policies and legislation

27 The future
George TJ Au, Clinical oncologist, Hong Kong; Neville Rigby and Rachel Jackson Leach, International Association for the Study of Obesity/International Obesity Task Force.

The history of cancer
George TJ Au, Clinical oncologist, Hong Kong; Brigitta Blaha Silva, Consul-General, Hong Kong; Chris Carrigan, National Cancer Registry Coordinator, UK.

For their diverse talents and editorial expertise, and individual as well as collective contributions, we would like to thank the team at Myriad Editions: Candida Lacey, Corinne Pearlman, Isabell Lewis, Janet King and Sadie Mayne.

Finally, we want to thank our respective families for their support during the preparation of this atlas.
Dr Judith Mackay is a medical doctor based in Hong Kong. She is a Senior Policy Advisor to the World Health Organization, and holds professorships at the Chinese Academy of Preventive Medicine in Beijing, and the Department of Community Medicine at the University of Hong Kong. After an early career as a hospital physician, she moved to working in preventive and public health. She is a Fellow of the Royal Colleges of Physicians of Edinburgh and of London. Dr Mackay has received many international awards, including the WHO Commemorative Medal, a Royal Award from the King of Thailand, the Fries Prize for Improving Health, the Luther Terry Award for Outstanding Individual Leadership, the International Partnering for World Health Award, and the Founding International Achievement Award from the Asia Pacific Association for the Control of Tobacco. She co-authored the first and second edition of *The Tobacco Atlas* and is the author of several other Myriad atlases, including *The State of Health Atlas*, *The Penguin Atlas of Human Sexual Behavior* and *The Atlas of Heart Disease and Stroke*.

Dr Ahmedin Jemal is Program Director of Cancer Occurrence at the American Cancer Society based in Atlanta. He currently holds an adjunct faculty position at the Rollins School of Public Health of Emory University, USA. His main research interests include cancer surveillance and stimulating the application of existing cancer control knowledge into practice. He is the author and co-author of many scientific articles in peer-reviewed journals.

Dr Nancy C Lee works as a consultant for the US Centers for Disease Control and Prevention (CDC) in the areas of public health, epidemiology, and cancer control. She has 24 years of experience with the CDC, and from 1999-2004 served as Director of CDC’s Division of Cancer Prevention and Control. Her efforts there focused on cancer surveillance, prevention, screening and early detection, and development of the USA’s public health efforts in cancer control.

Dr D Maxwell Parkin is an epidemiologist attached to the Clinical Trials Service Unit and Epidemiological Studies Unit at the University of Oxford, UK. He worked at the International Agency for Research on Cancer from 1981-2004 as head of the Descriptive Epidemiology Unit. He is currently President of the International Association of Cancer Registries (IACR). His main research interests are in descriptive epidemiology (international cancer patterns and trends), with a major concern for cancer registration, and in early detection (screening) for cancer. He has published more than 300 papers in the international scientific literature.
Adenocarcinoma – cancer that begins in cells that line the interior of hollow organs or ducts, such as the lining of a glandular (gland) organ (glandular). It is the most common type of harmful substance made by certain types of cells.

Age-standardized rate (ASR) – a measure of the proportion of persons in the age groups and the number of deaths from cancer that occur in a specified time period. It is expressed as a rate per 100,000.

Age-specific rate – a rate for a specified age group. The numerator and denominator refer to the same age group.

Age standardization – a technique that allows comparison of incidence (or mortality) rates between populations, without the effect of any differences that are due to their age structures.

Asbestos – a natural material that is made of tiny fibres and used in insulation. Asbestos exposure is a risk factor for several cancers, including lung cancer.

Benign tumour – an abnormal growth that is not cancer and does not spread to other areas of the body.

Body mass index (BMI) – a measure of a person's weight in relation to his or her height calculated as weight in kilograms divided by height in metres squared.

Cancer – a disease in which abnormal cells divide uncontrollably. Cancer cells can enter the bloodstream and lymphatic system and spread through the bloodstream and lymphatic system to other parts of the body.

Cancer screening programmes – programmes organized at the national and regional level that have (1) an explicit policy, (2) a team responsible for organizing the screening and delivering appropriate healthcare, and (3) a structure for assuring quality screening and follow-up of abnormal screening tests.

Chemotherapy – treatment with drugs to destroy cancer cells. Chemotherapy is usually given in combination with surgery or radiation, to treat cancer when the cancer has spread, when the cancer has come back (recurred), or when there is a strong chance that the cancer could return.

Cobalt-machines – use a radioactive form of the metal cobalt as a source of radiation to treat cancer.

Colonoscopy – examination of the colon with a long, flexible, lighted tube called a colonoscope. The doctor looks for polyps or early cancers during the exam and removes them using a wire passed through the colonoscope.

Computed tomography (CT) – a series of detailed pictures of areas inside the body taken from different angles; the pictures are created by a computer linked to an x-ray machine. Also called computed axial tomography (CAT) scan. A special kind of CT machine, the spiral CT, has been used to look for early lung cancer, but it is still uncertain whether such a test will be an effective cancer screening tool.

Developed countries – the United Nations Population Division divides the world's regions into two categories: more developed and less developed. The more developed regions include Australia/New Zealand, Europe, Northern America, and Japan.

Developing countries – the United Nations Population Division divides the world's regions into two categories: more developed and less developed. The less developed regions which this atlas calls “developing countries” include all the regions of Africa, Asia (excluding Japan), Latin America, and the Caribbean, as well as Melanesia, Micronesia, and Polynesia. The World Bank excludes “developing” regions such as affluent countries like Singapore.

Diagnosis – the process of identifying a disease by the signs and symptoms, as well as medical tests and tissue biopsy as needed.

Direct costs – expenditures for medical procedures and services associated with the treatment and care of people with cancer.

Electron accelerator machines – used in medical radiation therapy, these machines accelerate tiny charged particles called electrons, and deliver uniform doses of high-energy x-rays to the region of the patient's tumour. These x-rays can destroy the cancer cells while sparing the surrounding normal tissue.

Endometrial cancer – cancer of the layer of tissue that lines the uterus. A risk factor for endometrial cancer is exposure to excess amounts of the hormone oestrogen.

Exogenous hormones – hormones that are derived from outside the body, such as oral contraceptives and hormone replacement therapy.

Epidemic – occurrence of an illness, condition or behaviour that affects many people in the same region during a specified period of time. To constitute an epidemic, this occurrence must exceed normal occurrence in the region.

European Union 25 (EU-25) – Austria, Belgium, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Slovakia (Slovakia), Slovenia, Spain, Sweden and UK.

Facial occult blood test – a test used to screen for colorectal cancer. It looks for hidden blood in the stools, the presence of which could be a sign of cancer.

Hepatocellular carcinoma – the most common type of cancer originating in the liver.

Hormone replacement therapy (HRT) – hormones (oestrogen, progesterone, or other types) given to women after menopause to replace the hormones no longer produced by the ovaries.

Human papillomavirus (HPV) – a virus that can cause abnormal tissue growth and other changes to cells. Infection with certain types of HPV increases the risk of developing cervical cancer.

Incidence – the number of new cases of cancer that occur in a defined population during a specified period of time. “Incidence rate” is the rate at which new cases occur in a population, and is calculated by dividing the number of new cases that occur during a specified time period by the total number of people in the defined population.

Indirect costs – costs related to – but not immediately associated with – the detection, diagnosis and treatment of cancer. May include lost income due to premature death, short-term or long-term disability, and psychological costs.

Kaposi sarcoma – a type of cancer characterized by the abnormal growth of blood vessels that develop into skin lesions or occur internally. It is caused by Human herpesvirus-8. The risk of developing Kaposi sarcoma in a person who has Human herpesvirus-8 increases significantly if the person also has the virus that causes AIDS.

Leukaemia – cancer of the bone or blood-forming organs.

Lumpectomy – surgery to remove a breast lump or tumour and a small amount of surrounding normal tissue.

Lymphoma – a cancer of the lymphatic system. The lymphatic system is a network of thin vessels and nodes throughout the body. Two subtypes of lymphoma are Hodgkin lymphoma (or disease) and non-Hodgkin lymphoma. The treatment methods for these two types of lymphomas are different.

Malignant tumour – a mass of cancer cells that may invade surrounding tissues or spread (metastasize) to distant areas of the body.

Melanoma – a cancerous (malignant) tumour that begins in the cells that produce the skin coloring (melanocytes). Melanoma is almost always curable in its early stages. However, it is likely to spread, and since it has spread to other parts of the body the chances for a cure decrease.

Menarche – the first menstrual period, usually occurring during puberty.

Menopause – the time period marked by the permanent cessation of menstruation, usually occurring between the ages of 45 and 55.

Metastasis – the distant spread of cancer from its primary site to other parts of the body.

Morality – any departure from physiological or psychological well-being. Measures of morality for people living with cancer may include disability, pain, time away from work, or days spent in the hospital.

Mortality – the number of deaths from cancer that occur in a population during a specified period of time. The mortality rate is the rate at which deaths occur in a population, and is calculated by dividing the number of deaths that occur during a specified period of time by the number of people in the specified population.

Ovarian cancer – cancer occurring in one of a pair of female reproductive glands in which the ova, or eggs, are formed. The ovaries are located in the pelvis, one on each side of the uterus.

Neoplasm – an abnormal growth (tumour) that starts from a single altered cell, and a neoplasm may be benign or malignant.

Cancer is a malignant neoplasm.

Neuroblastoma – cancer that arises in immature nerve cells and affects mostly infants and children.

Palliative care – an approach that aims to improve the quality of life for patients and families facing the problems associated with life-threatening cancers. It provides for prevention and relief of suffering, through treatment for pain and other symptoms, as well as through spiritual and psychosocial support, at the time of cancer diagnosis, through the end of life, and during family bereavement.

Prevalence – a measure of the proportion of persons in the population with a certain disease, condition or behaviour at a given time.

Prognosis – prediction of the course of a cancer, and the outlook for a cure.

Radiotherapy – the use of radiation to kill cancer cells or stop them from dividing.

Radon – a radioactive gas that is released by uranium, a substance found in soil and rock. Radon is a risk factor for lung cancer.

Retinoblastoma – a rare form of eye cancer that affects the retina of infants and young children.

Sarcoma – cancer of the bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue.

Sigmoidoscopy – a test to help find cancer or polyps on the inside of the rectum and part of the colon. A slender, hollow, lighted tube is placed into the rectum. The doctor is able to look for polyps or other abnormalities. The sigmoidoscope is shorter than the colonoscope.

Solar irradiation – see ultraviolet radiation below.

Survival – the proportion (or percentage) of persons with a given cancer who are still alive after a specified time period (e.g. 1, 3, or 5 years) following diagnosis.

Total fertility rate – average number of births during a woman’s lifetime, given current childbearing patterns.

Ultraviolet (UV) radiation – invisible rays that are part of the energy that comes from the sun. UV radiation also comes from sun lamps and tanning booths. UV radiation can damage the skin, lead to premature aging, and cause melanoma and other types of skin cancer.

Wilms tumour – a type of kidney cancer that usually occurs in children younger than 3 years of age.